ArticleESMO real world data and digital oncology2023
SAPHIR: real-world clinical research platform for molecular testing, treatment, and clinical and patient-reported outcomes in patients with gastroesophageal cancer in Germany.
Article in ESMO real world data and digital oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Local and central testing for HER2, PD-L1, MSI/MMR, EBV, and CLDN18.2 in advanced gastric cancer: results from the SAPHIR registry.ESMO real world data and digital oncology · 2025Article
- Effect of Indocyanine Green-Guided Lymphadenectomy During Gastrectomy on Survival: Individual Patient Data Meta-Analysis.Cancers · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The treatment landscape of gastroesophageal cancer (GEC) is evolving. A better understanding of GEC biology and novel effective drugs would enhance the standard of care. To further improve outcomes for patients with GEC, it is crucial to evaluate treatment, response, survival, and patient-reported quality of life (QoL) in a real-world setting. Materials and methods: SAPHIR is a prospective and retrospective, observational, multicenter, national cohort study on esophageal, gastric, or gastroesophageal junction cancers. The study is aimed at enrolling 900 patients with stage IV GEC receiving first-line systemic therapy (prospective data collection). Patients are enrolled at ∼150 sites from different health care sectors in Germany. Recruitment started in quarter 4 (Q4)/2019. Each patient will be observed for a maximum of 2 years. In a satellite project, recruitment of another 200 patients with stage IB-III GEC receiving pre-/perioperative chemotherapy or radiochemotherapy was conducted in Q1-2/2022 (retrospective, one-time data collection). SAPHIR will provide real-world data (RWD) on treatment preferences, molecular testing, and clinical outcomes including overall and health-related QoL. Furthermore, patients can give consent for donation of tumor tissue obtained during the course of routine clinical care for centralized biomarker research. Descriptive statistics and explorative analyses will be carried out. Conclusions: SAPHIR aims to improve health care for patients with GEC by collecting RWD representative for all sectors in health care. This will provide information on routine clinical practice, efficacy, and evolving biomarker in GEC. Furthermore, evaluation of molecular data may allow for identification of response or resistance mechanisms to targeted and immunotherapy in GEC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.